This study is currently not recruiting participants.

Developing protocol for hydroxyurea detection in plasma of sickle cell patients

  • STATUS
    Not Recruiting
Updated on 19 February 2024

Summary

We are conducting this study to develop a protocol for the detection of hydroxyurea plasma. Hydroxyurea is the only FDA approved disease-modifying agent for children with sickle cell disease, and requires careful titration to maximize clinical benefit and minimize adverse effects. Unfortunately, there is considerable variability in the maximum tolerated dose (MTD), and often a delay of 6 to 12 months until patients reach his or her MTD. The research team at Purdue is looking at developing a pharmacokinetic-pharmacodynamic model of hydroxyurea to help clinicians with optimizing the dose for every individual. For the pharmacokinetic study, we need to measure hydroxyurea concentration in plasma within 4-8 hours of taking the drug. The hydroxyurea detection will happen at Bindley Bioscience Center. In order to measure the hydroxyurea concentration in plasma, we need to develop the protocol for it.

Description

We are conducting this study to develop a protocol for the detection of hydroxyurea plasma. Hydroxyurea is the only FDA approved disease-modifying agent for children with sickle cell disease, and requires careful titration to maximize clinical benefit and minimize adverse effects. Unfortunately, there is considerable variability in the maximum tolerated dose (MTD), and often a delay of 6 to 12 months until patients reach his or her MTD. The research team at Purdue is looking at developing a pharmacokinetic-pharmacodynamic model of hydroxyurea to help clinicians with optimizing the dose for every individual. For the pharmacokinetic study, we need to measure hydroxyurea concentration in plasma within 4-8 hours of taking the drug. The hydroxyurea detection will happen at Bindley Bioscience Center. In order to measure the hydroxyurea concentration in plasma, we need to develop the protocol for it.

Details
Condition sickle cell disease
Age 100years or below
Clinical Study IdentifierTX8679
Last Modified on19 February 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.